Combination therapy continues to evolve in the renal-cell carcinoma space. However, along with improved efficacy come the tests of adverse events and their impact on quality of life. Please join Laura Wood, RN, MSN, OCN, Virginia Seery, MSN, RN, ANP-BC, AOCNP, and Megan Price, MSN, APRN, FNP-C, as they discuss the ways in which drug combinations improve outcomes but also present their own set of challenges for patients’ quality of life.
Baylor Charles A. Sammons Cancer Center
Beth Israel Deaconess Medical Center, Harvard Medical School Teaching Hospital, Boston, MA
Cleveland Clinic Taussig Cancer Center
Last modified: June 21, 2021